NCT04564898 2026-01-08
TriComB
Gruppo Oncologico del Nord-Ovest
Phase 1/2 Active not recruiting
Clinical Trials
6 trialsNCT04031872 2025-09-05
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT04940546 2024-12-03
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
Sun Yat-sen University
Phase 1/2 Active not recruiting
NCT04751955 2023-10-31
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
Korean Cancer Study Group
Phase 1/2 Withdrawn
NCT03470350 2019-07-24
EORTC1615
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT01955629 2016-04-18
AMOR
Sanofi
Phase 1/2 Terminated